Health Care·Biotechnology·$5.7B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.19 | N/A | +34.48% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.19 | N/A | +34.48% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Management conveyed a cautious optimism regarding their clinical progress. They emphasized their focus on advancing their pipeline and maintaining momentum.
Management highlighted progress in ongoing clinical trials.
They noted a strong commitment to advancing their pipeline.
They expressed confidence in future developments despite current challenges.
PTC Therapeutics reported a narrower-than-expected loss per share, which was a positive surprise for investors. However, the stock fell by 2.7%, likely due to the absence of revenue data and lack of forward guidance. Investors may be concerned about the company's future performance without clearer direction.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
RADNET INC
Nov 11, 2013